Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Recruiting now · Not applicable
Conditions studied: Lymphoproliferative Disorder, Multiple Myeloma
In brief
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.
Key facts
- Study ID
- NCT06630104
- Run by
- Mayo Clinic
- People needed
- 82
- Starts
- 2024-11-22
- Expected to finish
- 2027-12-16
- Last updated by the study team
- 2026-01-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined in International Myeloma Working Group (IMWG) criteria or a CD19+ lymphoproliferative disorder (LPD) as defined by 2016 World Health Organization (WHO) classification
- Provide written informed consent
- Willingness to provide mandatory bone marrow aspirate specimens for correlative research. All bone marrow aspirate samples are collected during a clinical procedure
- Willingness to provide mandatory hair follicle specimens for correlative research
- Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- Willingness to provide saliva and buccal samples for research
You may not qualify if…
- Ineligible for CAR-T therapy
- Patients diagnosed with myeloid neoplasm before CAR-T therapy
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States (enrolling)
- Mayo Clinic in Florida — Jacksonville, Florida, United States (enrolling)
- Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota, United States (enrolling)
- Mayo Clinic Health System-Mankato — Mankato, Minnesota, United States (enrolling)
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)
- Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin, United States (enrolling)
- Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.